Nanoformulations for Treating HIV-Associated Neurocognitive Disorders

TECHNOLOGY OPPORTUNITY
IP 1656- Magneto-electric liposome formulations for the delivery of miR-107, WA, and BD1063 across the BBB

Magneto-electric liposome formulations for the delivery of miR-107, WA, and BD1063 across the BBB

Florida International University (FIU) is seeking a business partner to develop and commercialize novel therapeutic compositions against HIV-Associated Neurocognitive Disorders (HAND), and particularly, in HIV patients using cocaine.

With proper medications, human immunodeficiency virus (HIV) patients now live almost full lifespans; however, HAND continues and its prevalence is increasing. This may be, in part, because HIV infection remains in the brain. Anti-retroviral therapies (ARV) improve cognition and reduce the prevalence of HIV-associated dementia; however, continued HIV infection and aging process exacerbate the incidence of HAND. Since the beginning of the epidemic, drug abuse and HIV infecti

 IP 1656- Effect of WA on HIV-1 suppression and its cytotoxicity in microglial (CHME-5) cell ± HIV

Effect of WA on HIV-1 suppression and its cytotoxicity in microglial (CHME-5) cell ± HIV

on have been inextricably linked, and neurocognitive dysfunction is enhanced in HIV patients that are ingesting cocaine and other drugs of abuse. Cocaine causes neuronal impairments as well as increases the incidence and severity of HAND. Despite significant therapeutic advances made in the management of HIV, effective treatments against HIV infection in the brain and the pathogenesis of HAND remains a tremendous task.

FIU inventors have developed formulations and methods based on bifunctional plant molecule, Withaferine-A (WA), which can eradicate HIV and remove neuronal amyloid beta (Aβ) protein. The formulations comprise magnetic nanoparticles (MENPs) encapsulated with liposomes, and conjugated to or mixed with therapeutic cargos comprising an HIV inhibitor (WA), an inhibitor of beta-secretase 1 (BACE-1) activity or expression, and a cocaine antagonist. Because of the high magnetic moments of the MENPs, the formulations can deliver therapeutic cargos to desired body areas including across the blood brain barrier (BBB) via the application of noninvasive external magnetic forces. The components of the therapeutic cargos are then sequentially released from liposomes via biodegradation or diffusion, and alternating current (a.c.) trigger stimulation.

APPLICATIONS
  • Treatment or prevention of amyloid plaque mediated neuronal dysfunction in HIV infected HAND patients
ADVANTAGES
  • Allows for non-invasive delivery of therapeutic cargo to desired body areas including across the blood brain barrier
  • Permits the sequential release of several therapeutic components from one single biocompatible nanoformulation
QUESTIONS ABOUT THIS TECHNOLOGY

Call Anne-Laure “Anlo” Schmitt-Olivier at 305-348-5948 or fill out the quick contact form below.